Featured ArticlesThe Latest

Cross-Sectional Analysis of Adverse Dermatologic Events Reported to the FDA After Use of GLP-1 Agonists

By September 25, 2024September 29th, 2024No Comments
Journal of Drugs in Dermatology JDD article about Cross-Sectional Analysis of Adverse Dermatologic Events Reported to the FDA After Use of GLP-1 Agonists. The most frequent reactions were rash, pruritus, and alopecia. Links to Inclusive Derm Atlas for alopecia hair related pictures.

JDD Article Highlight

JDD’s article titled, “Cross-Sectional Analysis of Adverse Dermatologic Events Reported to the FDA After Use of GLP-1 Agoniststouches upon a significant increase in the use of GLP-1 agonists, like semaglutide and liraglutide, for weight loss has led to a rise in dermatologic adverse events, with over 6% of reported side effects being skin-related. Liraglutide was the most common culprit, followed by semaglutide and tirzepatide. The most frequent reactions were rash, pruritus, and alopecia. As these medications become more popular, it’s crucial for dermatologists to be aware of potential skin-related side effects when counseling patients.